cells

COMBINING TO CURE®

Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.

We’re combining
therapeutic strategies

to activate the immune system to recognize and eradicate cancer, which we believe has the potential to achieve cures that have eluded medicine for decades.

We’re combining
our expertise

across scientific disciplines to discover innovative, best-in-class medicines and to design combination therapies guided by specific biologic profiles of cancer.

We’re combining with the medical community

and with patients and their caregivers to facilitate participation in our clinical trials and bring breakthrough medicines to patients faster.

Joining forces to defeat cancer.
This is COMBINING TO CURE®

Arcus clinical trials are currently enrolling

Learn More

 arrow

Join forces with us on our mission to defeat cancer

Learn More

 arrow

Read our latest press releases and announcements

Learn More

 arrow

CLINICAL PIPELINE

Indication View
Molecule View
Indication
Study
Line & Regimena,b
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

NSCLC

Study:
arc-7
Line & Regimena,b :
WT 1L, PD-L1 ≥ 50% ,  
dom + zim ± etruma
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Study:
arc-4
Line & Regimena,b :
EGFRm 2L+ ,  
etruma + zim + carbo/pem
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Study:
arc 10
Line & Regimena,b :
WT 1L, PD-L1 ≥ 50% ,  
dom + zim vs. zim vs. chemo
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

mCRPC

Study:
arc-6
Line & Regimena,b :
1L ,  
etruma + zim + enza
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Study:
arc-6
Line & Regimena,b :
2L+ ,  
etruma + zim + doce
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Study:
arc-6
Line & Regimena,b :
2L+ ,  
etruma + zim
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Study:
arc-6
Line & Regimena,b :
2L+ ,  
etruma + zim + quemli
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

CRC

Study:
Arc-9
Line & Regimena,b :
2L ,  
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Study:
Arc-9
Line & Regimena,b :
3L ,  
etruma + zim + FOLFOX* vs. Rego
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Study:
Arc-9
Line & Regimena,b :
>3L ,  
etruma combinations
Phase 1
Phase 1b
Randomized/
Phase 2
Pivtotal/
Phase 3
Indication:

PDAC

Study:
arc-8
Line & Regimena,b :
1L ,  
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

Advanced Malignancies

Study:
arc 12
Line & Regimena,b :

AB308 + zim
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Indication:

Healthy Participants

Study:
arc 14
Line & Regimena,b :

AB521
Phase 1
Phase 1b
Randomized/
Phase 2
Pivotal/
Phase 3
Moleculea,b
Indication
Study
Line & Regimen
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY
Indication:

NSCLC

Study:
arc-7
Line & Regimen:
1L ,  
dom + zim ± etruma
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Study:
arc 10
Line & Regimen:
WT 1L, PD-L1 ≥ 50% ,  
dom + zim vs. zim vs. chemo
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

Multiple Cancer Types

Study:

See Clinical Trial

Line & Regimen:
2L+ ,  
dom + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

AB308

FC-ENABLED ANTI-TIGIT ANTIBODY
Indication:

Advanced Malignancies

Study:
arc 12
Line & Regimen:

AB308 + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

Quemliclustat

CD73 Inhibitor Small Molecule
Indication:

PDAC

Study:
arc-8
Line & Regimen:
1L ,  
quemli + zim + gem/nab-pac
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

Etrumadenant
(ETRUMA)

Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule
Indication:

CRPC

Study:
arc-6
Line & Regimen:
1L+ ,  
etruma + zim ± enza
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRPC

Study:
arc-6
Line & Regimen:
2L+ ,  
etruma + zim + doce
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRPC

Study:
arc-6
Line & Regimen:
2L+ ,  
etruma + zim
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRPC

Study:
arc-6
Line & Regimen:
2L+ ,  
etruma + zim + quemli
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Study:
Arc-9
Line & Regimen:
2L ,  
etruma + zim + FOLFOX* vs. FOLFOX*
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Study:
Arc-9
Line & Regimen:
3L ,  
etruma + zim + FOLFOX* vs. Rego
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

CRC

Study:
Arc-9
Line & Regimen:
>3L ,  
etruma combinations
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Study:
arc-4
Line & Regimen:
EGFRm 2L+ ,  
etruma + zim + carbo/pem
Phase 1
Phase 1b
Phase 2
Phase 3
Indication:

NSCLC

Study:
arc-7
Line & Regimen:
1L ,  
dom + zim ± etruma
Phase 1
Phase 1b
Phase 2
Phase 3
Moleculea,b :

AB521

HIF-2𝛂 Inhibitor
Indication:

Healthy Participants

Study:
arc 14
Line & Regimen:

AB521
Phase 1
Phase 1b
Phase 2
Phase 3


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Quemli: quemliclustat; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

||Clinical collaboration with Infinity Pharmaceuticals.
*+/- biologic


Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
Dom: domvanalimab; Etruma: etrumadenant; Zim: zimberelimab; Quemli: quemliclustat; Doce: docetaxel; Enza: enzalutamide; Atezo: atezolizumab; Rego: regorafenib; Carbo/Pem: carboplatin/pemetrexed; Bev: bevacizumab; Gem/Nab-pac: gemcitabine/nab-paclitaxel; PLD: pegylated liposomal doxorubicin; SOC: standard of care

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma;

PARTNERSHIPS & COLLABORATIONS:

gilead logo (a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

taiho logo (b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

||Clinical collaboration with Infinity Pharmaceuticals.
*+/- biologic

DISCOVERY PIPELINE

Immuno-Oncology Target

icon

CD39

Exo-nucleotidase

CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1

Additional undisclosed targets.

Cancer Cell Intrinsic Target

icon

HIF-2𝛂 Inhibitor

Transcription factor

HIF-2α is a master transcriptional regulator of multiple genes involved in tumor progression.2

icon

AXL Inhibitor

Tyrosine kinase

AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.3

Additional undisclosed targets.

HIF-2𝛂, hypoxia-inducible factor 2-alpha

References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739–755 (2020). 2. Murugesan T, Rajajeyabalachandran G, Kumar S, Nagaraju S, Kumar S. Targeting HIF-2α as therapy for advanced cancers. Drug Discov Today. 2018;23(7):1444-1451. 3. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.

Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc.
© 2020 Arcus Biosciences, Inc.  All rights reserved.
3928 Point Eden Way, Hayward, CA 94545